영국 - 영어 - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - nicotine - transdermal patch - 5mg/16hour

영국 - 영어 - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - nicotine - transdermal patch - 10mg/16hour

영국 - 영어 - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - nicotine - transdermal patch - 15mg/16hour

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - estradiol, quantity: 1.56 mg - drug delivery system, transdermal - excipient ingredients: dipropylene glycol; povidone; oleyl alcohol; ethyl acetate; simethicone; dimeticone; xylene; cyclomethicone; toluene; acrylates/va copolymer; ethylene/vinyl acetate copolymer; 1,1-dichloroethylene, chloroethylene polymer; polyethylene; sodium carbonate; polyethylene terephthalate; polyvinylidene flouride - short term treatment of symptoms of oestrogen deficiency due to the menopause, whether natural or surgically induced. in women with an intact uterus, oestrogen should always be opposed by progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals (see clinical trails and dosage and administration). combination hrt should not be used in hysterectomised women because it is not needed in these women and it may increase the risk of breast cancer.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - estradiol, quantity: 1.17 mg - drug delivery system, transdermal - excipient ingredients: dipropylene glycol; povidone; oleyl alcohol; ethyl acetate; simethicone; dimeticone; xylene; cyclomethicone; toluene; acrylates/va copolymer; ethylene/vinyl acetate copolymer; 1,1-dichloroethylene, chloroethylene polymer; polyethylene; sodium carbonate; polyethylene terephthalate; polyvinylidene flouride - short term treatment of symptoms of oestrogen deficiency due to the menopause, whether natural or surgically induced. in women with an intact uterus, oestrogen should always be opposed by progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals (see clinical trails and dosage and administration). combination hrt should not be used in hysterectomised women because it is not needed in these women and it may increase the risk of breast cancer.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - estradiol, quantity: 0.78 mg - drug delivery system, transdermal - excipient ingredients: dipropylene glycol; povidone; oleyl alcohol; ethyl acetate; simethicone; dimeticone; xylene; cyclomethicone; toluene; acrylates/va copolymer; ethylene/vinyl acetate copolymer; 1,1-dichloroethylene, chloroethylene polymer; polyethylene; sodium carbonate; polyethylene terephthalate; polyvinylidene flouride - short term treatment of symptoms of oestrogen deficiency due to the menopause, whether natural or surgically induced. in women with an intact uterus, oestrogen should always be opposed by progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals (see clinical trails and dosage and administration). combination hrt should not be used in hysterectomised women because it is not needed in these women and it may increase the risk of breast cancer.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - estradiol, quantity: 0.585 mg - drug delivery system, transdermal - excipient ingredients: dipropylene glycol; povidone; oleyl alcohol; ethyl acetate; simethicone; dimeticone; xylene; cyclomethicone; toluene; acrylates/va copolymer; ethylene/vinyl acetate copolymer; 1,1-dichloroethylene, chloroethylene polymer; polyethylene; sodium carbonate; polyethylene terephthalate; polyvinylidene flouride - short term treatment of symptoms of oestrogen deficiency due to the menopause, whether natural or surgically induced. in women with an intact uterus, oestrogen should always be opposed by progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals (see clinical trails and dosage and administration). combination hrt should not be used in hysterectomised women because it is not needed in these women and it may increase the risk of breast cancer.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - estradiol, quantity: 0.39 mg - drug delivery system, transdermal - excipient ingredients: dipropylene glycol; povidone; oleyl alcohol; ethyl acetate; simethicone; dimeticone; xylene; cyclomethicone; toluene; acrylates/va copolymer; ethylene/vinyl acetate copolymer; 1,1-dichloroethylene, chloroethylene polymer; polyethylene; sodium carbonate; polyethylene terephthalate; polyvinylidene flouride - short term treatment of symptoms of oestrogen deficiency due to the menopause, whether natural or surgically induced. in women with an intact uterus, oestrogen should always be opposed by progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals (see clinical trails and dosage and administration). combination hrt should not be used in hysterectomised women because it is not needed in these women and it may increase the risk of breast cancer.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - estradiol, quantity: 1.56 mg - drug delivery system, transdermal - excipient ingredients: dipropylene glycol; povidone; oleyl alcohol; ethyl acetate; simethicone; dimeticone; xylene; cyclomethicone; toluene; acrylates/va copolymer; polyethylene terephthalate; polyvinylidene flouride; colloidal anhydrous silica; butylated hydroxytoluene; 2,6-di-tert-butyl-4-ethylphenol; calcium stearoyl lactylate; epoxidised soy oil; erucamide; ethylene/vinyl acetate copolymer; magnesium hydroxide; octadecyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate; polyethylene; silica; stearamide; synthetic paraffin; tetrasodium pyrophosphate; vinyl acetate; quartz; 1,1-dichloroethylene, chloroethylene polymer; diatomaceous earth; oxidised polyethylene - short term treatment of symptoms of oestrogen deficiency due to the menopause, whether natural or surgically induced. in women with an intact uterus, oestrogen should always be opposed by progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals (see clinical trails and dosage and administration). combination hrt should not be used in hysterectomised women because it is not needed in these women and it may increase the risk of breast cancer.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - estradiol, quantity: 1.17 mg - drug delivery system, transdermal - excipient ingredients: dipropylene glycol; povidone; oleyl alcohol; ethyl acetate; simethicone; dimeticone; xylene; cyclomethicone; toluene; acrylates/va copolymer; polyethylene terephthalate; polyvinylidene flouride; colloidal anhydrous silica; butylated hydroxytoluene; 2,6-di-tert-butyl-4-ethylphenol; calcium stearoyl lactylate; epoxidised soy oil; erucamide; ethylene/vinyl acetate copolymer; magnesium hydroxide; octadecyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate; polyethylene; silica; stearamide; synthetic paraffin; tetrasodium pyrophosphate; vinyl acetate; quartz; 1,1-dichloroethylene, chloroethylene polymer; diatomaceous earth; oxidised polyethylene - short term treatment of symptoms of oestrogen deficiency due to the menopause, whether natural or surgically induced. in women with an intact uterus, oestrogen should always be opposed by progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals (see clinical trails and dosage and administration). combination hrt should not be used in hysterectomised women because it is not needed in these women and it may increase the risk of breast cancer.